Cellosaurus logo
expasy logo

Cellosaurus PS-1 [Human urinary bladder carcinoma] (CVCL_4892)

[Text version]
Cell line name PS-1 [Human urinary bladder carcinoma]
Synonyms PS1; PSI
Accession CVCL_4892
Resource Identification Initiative To cite this cell line use: PS-1 [Human urinary bladder carcinoma] (RRID:CVCL_4892)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: UBC-40 urothelial bladder cancer cell line index.
Omics: Deep exome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 63Y
Category Cancer cell line
STR profile Source(s): PubMed=11416159; PubMed=27270441

Markers:
AmelogeninX,Y
CSF1PO12,13
D5S81812
D7S8209,13
D8S117911,13
D13S31712
D16S5399,11
D18S5111,12
D21S1130,31.2
FGA23
TH017,8
TPOX9
vWA15,16

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/UC25
Publications

PubMed=81814
Sanford E.J., Geder L., Dagen J.E., Laychock A.M., Ladda R.L., Rohner T.J. Jr.
Establishment and characterization of a new human urinary bladder carcinoma cell line (PS-1).
Invest. Urol. 16:246-252(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052
Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Eur. Urol. 65:360-366(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

Cross-references
Encyclopedic resources Wikidata; Q54948399
Gene expression databases GEO; GSM136241
Polymorphism and mutation databases Cosmic; 2037953
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number16